Antithrombotic- and Thrombolytic-Related Intracerebral Hemorrhage

  • Jan C. Purrucker
  • Matthew L. Flaherty
  • Gustavo Rodriguez
  • Saqib Chaudhry
  • Fazeel Siddiqui
  • Thorsten SteinerEmail author


Intracerebral hemorrhage related to anticoagulant therapy represents a neurologic emergency. This chapter reviews the evidence of anticoagulation reversal treatment and further elucidates management of intracerebral hemorrhage occurring in relation to antithrombotic treatment and thrombolysis, as well as heparin. Prothrombin concentrate can effectively reverse vitamin K antagonist therapy and should be immediately administered in acute intracerebral hemorrhage associated with vitamin K antagonist therapy. For non-vitamin K antagonist-associated intracerebral hemorrhage, recent observational data show a similar rate of hematoma expansion than with vitamin K antagonists. Specific antidotes for non-vitamin K antagonist reversal are either available (idarucizumab for reversal of dabigatran) or in development (for factor Xa inhibitors). Importantly, in case of intracerebral hemorrhage associated with antiplatelet therapy, cessation of antiplatelet therapy seems sufficient in most cases, and platelet infusions should not be given. Despite all recent advances, anticoagulation-related intracerebral hemorrhage still is associated with unfavorable clinical outcome and further efforts need to be taken to define the optimal medical management.


Intracranial hemorrhage Intracerebral hemorrhage Anticoagulation Antithrombotic Stroke Thrombolysis Cerebrovascular disease Bleeding Neurologic emergency Vitamin K antagonist Non-vitamin K antagonist oral anticoagulant 


  1. 1.
    Fisher CM. Hypertensive cerebral hemorrhage. Demonstration of the source of bleeding. J Neuropathol Exp Neurol. 2003;62(1):104–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011;7(1):1–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012;83(2):124–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Greenberg SM, Nandigam RN, Delgado P, Betensky RA, Rosand J, Viswanathan A, et al. Microbleeds versus macrobleeds: evidence for distinct entities. Stroke. 2009;40(7):2382–6.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kovari E, Charidimou A, Herrmann FR, Giannakopoulos P, Bouras C, Gold G. No neuropathological evidence for a direct topographical relation between microbleeds and cerebral amyloid angiopathy. Acta Neuropathol Commun. 2015;3:49.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Schlunk F, Greenberg SM. The pathophysiology of intracerebral hemorrhage formation and expansion. Transl Stroke Res. 2015;6(4):257–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Greenberg CH, Frosch MP, Goldstein JN, Rosand J, Greenberg SM. Modeling intracerebral hemorrhage growth and response to anticoagulation. PLoS One. 2012;7(10):e48458.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Horstmann S, Rizos T, Lauseker M, Mohlenbruch M, Jenetzky E, Hacke W, et al. Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study. J Neurol. 2013;260(8):2046–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Bejot Y, Cordonnier C, Durier J, Aboa-Eboule C, Rouaud O, Giroud M. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain. 2013;136(Pt 2):658–64.CrossRefPubMedGoogle Scholar
  12. 12.
    Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68(2):116–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71(14):1084–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE, et al. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology. 2011;76(14):1238–44.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Biffi A, Battey TW, Ayres AM, Cortellini L, Schwab K, Gilson AJ, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology. 2011;77(20):1840–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pezzini A, Grassi M, Paciaroni M, Zini A, Silvestrelli G, Del Zotto E, et al. Antithrombotic medications and the etiology of intracerebral hemorrhage: MUCH-Italy. Neurology. 2014;82(6):529–35.CrossRefPubMedGoogle Scholar
  18. 18.
    Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care. 2006;5(3):197–201.CrossRefPubMedGoogle Scholar
  19. 19.
    Hanger HC, Fletcher VJ, Wilkinson TJ, Brown AJ, Frampton CM, Sainsbury R. Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. J Neurol. 2008;255(3):347–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Drouet L, Bal Dit Sollier C, Steiner T, Purrucker J. Measuring non-vitamin K antagonist oral anticoagulant levels: when is it appropriate and which methods should be used? Int J Stroke. 2016;11(7):748–58.CrossRefPubMedGoogle Scholar
  21. 21.
    Rizos T, Jenetzky E, Herweh C, Hug A, Hacke W, Steiner T, et al. Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Ann Neurol [Clinical Trial]. 2010;67(6):788–93.Google Scholar
  22. 22.
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):204S–33S.CrossRefPubMedGoogle Scholar
  23. 23.
    Neal M, Crowther M, Douketis J, Verhovsek M, Stidley C, Garcia D. Reversal of vitamin K antagonist-associated coagulopathy: a survey of current practice. Thromb Res. 2008;122(6):864–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res. 2012;130(6):833–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of Antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical care society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6–46.CrossRefPubMedGoogle Scholar
  26. 26.
    Laible M, Jenetzky E, Beynon C, Muller OJ, Sander P, Schuler S, et al. Adverse events following international normalized ratio reversal in intracerebral hemorrhage. Cerebrovasc Dis. 2016;42(5–6):446–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–87.CrossRefGoogle Scholar
  28. 28.
    Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–43.PubMedGoogle Scholar
  29. 29.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMedGoogle Scholar
  30. 30.
    Pfeilschifter W, Farahmand D, Niemann D, Ikenberg B, Hohmann C, Abruscato M, et al. Estimating the quantitative demand of NOAC antidote doses on stroke units. Cerebrovasc Dis. 2016;42(5–6):415–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol. 2016;73(2):169–77.CrossRefPubMedGoogle Scholar
  32. 32.
    Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology. 2017;88(18):1693–700.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Purrucker JC, Rizos T, Haas K, Wolf M, Khan S, Heuschmann PU, et al. Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants. Neurocrit Care. 2017;27:208.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42(12):3594–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhou W, Zorn M, Nawroth P, Butehorn U, Perzborn E, Heitmeier S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013;44(3):771–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care. 2016;20(1):115.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation [Comparative Study]. 2011;124(14):1573–9.CrossRefGoogle Scholar
  38. 38.
    Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–90.CrossRefPubMedGoogle Scholar
  39. 39.
    Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Med. 2016;129(11S):S64–72.CrossRefPubMedGoogle Scholar
  40. 40.
    Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511–20.CrossRefPubMedGoogle Scholar
  41. 41.
    Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431–41.CrossRefPubMedGoogle Scholar
  42. 42.
    Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–41.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2–10.CrossRefPubMedGoogle Scholar
  44. 44.
    Gumbinger C, Gruschka P, Bottinger M, Heerlein K, Barrows R, Hacke W, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke. 2012;43(1):240–2.CrossRefPubMedGoogle Scholar
  45. 45.
    von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD, et al. The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015;46(10):2981–6.CrossRefGoogle Scholar
  46. 46.
    Whiteley WN, Emberson J, Lees KR, Blackwell L, Albers G, Bluhmki E, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15(9):925–33.CrossRefPubMedGoogle Scholar
  47. 47.
    Yaghi S, Boehme AK, Dibu J, Leon Guerrero CR, Ali S, Martin-Schild S, et al. Treatment and outcome of thrombolysis-related hemorrhage: a multicenter retrospective study. JAMA Neurol. 2015;72(12):1451–7.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605–13.CrossRefPubMedGoogle Scholar
  49. 49.
    Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996;27(10):1783–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66(8):1175–81.CrossRefPubMedGoogle Scholar
  52. 52.
    Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127–37.CrossRefPubMedGoogle Scholar
  53. 53.
    Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P, Investigators C. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39(11):2993–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke. 2011;42(9):2431–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jan C. Purrucker
    • 1
  • Matthew L. Flaherty
    • 2
  • Gustavo Rodriguez
    • 3
  • Saqib Chaudhry
    • 4
  • Fazeel Siddiqui
    • 5
  • Thorsten Steiner
    • 1
    • 6
    Email author
  1. 1.Department of NeurologyHeidelberg University HospitalHeidelbergGermany
  2. 2.Department of Neurology and Rehabilitation MedicineUniversity of Cincinnati, Academic Health CenterCincinnatiUSA
  3. 3.Department of NeurologyTexas Tech UniversityEl PasoUSA
  4. 4.Departments of Neurology and Neuro-critical CareUniversity of PennsylvaniaPhiladelphiaUSA
  5. 5.Department of NeurologySouthern Illinois UniversitySpringfieldUSA
  6. 6.Department of NeurologyKlinikum Frankfurt HöchstFrankfurt a.M.Germany

Personalised recommendations